Screener
Pfizer PFE Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenues: by Product | ||||||
| Abrysvo | $208M+45.5% | $180M+37.4% | $480M+142% | $279M-21.6% | $143M+155% | |
| Adcetris | $196M-23.1% | $190M-12.8% | $220M-22.8% | $215M-19.8% | $255M-8.6% | |
| All Other Hospital and Biosimilars | $952M— | $953M+5.8% | —— | —— | —— | |
| All other Primary Care | $699M-5.0% | $654M+7.4% | $789M+0.3% | $721M-2.8% | $736M-3.0% | |
| All other Specialty Care | $566M+45.1% | $579M+19.1% | $476M+38.4% | $407M+26.0% | $390M-9.1% | |
| Bosulif | $113M-24.2% | $129M-14.6% | $161M-5.8% | $150M-6.8% | $149M-10.8% | |
| Braftovi/Mektovi | $223M+22.5% | $174M+27.9% | $197M+15.9% | $202M+16.8% | $182M+23.0% | |
| Cibinqo | $94M+36.2% | $76M+31.0% | $78M+23.8% | $79M+25.4% | $69M+46.8% | |
| Eliquis | $2.43B+21.1% | $2.17B+12.6% | $2.02B+10.3% | $2.02B+24.6% | $2B+6.7% | |
| Elrexfio | $89M+4.7% | $80M+33.3% | $74M+29.8% | $85M+113% | $85M+286% | |
| Enbrel (Outside the U.S. and Canada) | $142M-7.8% | $138M-1.4% | $179M-2.2% | $154M-8.9% | $154M-14.0% | |
| Genotropin | $94M-11.3% | $93M-2.1% | $117M+4.5% | $128M+7.6% | $106M-10.9% | |
| Ibrance | $1.06B+0.9% | $1.01B+3.2% | $1.04B-5.1% | $1.06B-2.8% | $1.05B-7.2% | |
| Inflectra | $171M+23.0% | $182M+19.0% | —— | $173M+37.3% | $139M+43.3% | |
| Inlyta | $218M-10.3% | $214M-2.3% | $235M-2.9% | $226M-8.5% | $243M-3.6% | |
| Lorbrena | $354M+41.0% | $305M+37.4% | $282M+46.1% | $268M+30.1% | $251M+48.5% | |
| Nurtec ODT/Vydura | $421M+17.3% | $353M+42.3% | $405M+3.1% | $412M+22.3% | $359M+0.8% | |
| Octagam | $138M+42.3% | $122M+38.6% | $120M+10.1% | $113M-48.9% | $97M-6.7% | |
| Oncology Biosimilars | $359M+1.7% | $409M+54.9% | $369M+76.6% | $315M+10.5% | $353M+26.5% | |
| Orgovyx | $146M+50.5% | $109M+43.4% | $136M+109% | $112M+96.5% | $97M— | |
| Padcev | $667M+23.1% | $591M+38.7% | $508M+14.4% | $464M+13.4% | $542M+37.6% | |
| Paxlovid | $21M-95.1% | $186M-62.1% | —— | $1.23B-54.7% | $427M+70.1% | |
| Sulperazon (Outside the U.S. and Canada) | $116M-30.1% | $199M+21.3% | $169M0.0% | $154M-1.3% | $166M+15.3% | |
| Talzenna | $57M+23.9% | $50M+25.0% | $49M+88.5% | $47M+30.6% | $46M+43.8% | |
| Tivdak | $34M-26.1% | $33M0.0% | $32M-13.5% | $37M+8.8% | $46M+39.4% | |
| Tukysa | $138M+4.5% | $122M+19.6% | $119M-7.8% | $110M-11.3% | $132M+9.1% | |
| Vyndaqel family | $1.76B+9.1% | $1.6B+7.8% | $1.69B+9.3% | $1.59B+10.0% | $1.62B+22.1% | |
| Xeljanz | $251M-22.0% | $180M+40.6% | $324M-7.4% | $313M-2.5% | $322M+6.3% | |
| Xtandi | $534M-5.7% | $444M-3.1% | $592M+4.8% | $578M+3.0% | $566M+14.3% | |
| Zavicefta (Outside the U.S. and Canada) | $199M+22.1% | $150M+11.1% | $181M+13.8% | $158M+3.9% | $163M+8.7% |
FAQ
- How does Pfizer break its business down?
- Pfizer (PFE) reports revenues: by product across 36 parts — Abrysvo, Adcetris, All Other Hospital and Biosimilars, All other Oncology and All other Primary Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Pfizer's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pfizer's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
